Efficacy of Tocilizumab in Conventional Treatment–Refractory Adult‐Onset Still's Disease: Multicenter Retrospective Open‐Label Study of Thirty‐Four Patients

Sanjuán, Francisco Miguel Ortíz; Blanco, R.; Calvo-Río, V.; Narváez, Javier; Romero, Esteban Rubio; Olivé, Alejandro; Castañeda, Santos; Flores, Adela Gallego; Hernández, M. Victoria; Mata, Cristina; Vilamajó, Inmaculada Ros; Giraldo, Walter Alberto Sifuentes; Caracuel, Miguel A.; Freire, Mercedes; Arango, C. Gómez; Llobet, José; Arija, S. Manrique; Marras, Carlos; Moll-Tuduri, Concepción; Plasencia-Rodríguez, Chamaida; Roselló, Rosa; Urruticoechea, Ana; Velloso-Feijoó, María Luisa; Blanco, Jordi del; González‐Vela, M. Carmen; Rueda-Gotor, Javier; Pina, Trinitario; Loricera, J.

doi:10.1002/art.38398

Cited by 119 publications

(65 citation statements)

References 13 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, there was no significant difference in potency of tocilizumab monotherapy with or without MTX in RA patients [83]. In addition to targeting RA, the anti-IL-6 approach has also been used to treat patients with other autoimmune diseases such as juvenile idiopathic arthritis [84] and adult-onset Still's disease [85]. …”

Section: Page 26 Of 64mentioning

confidence: 98%

Biological effects of interleukin-6: Clinical applications in autoimmune diseases and cancers

Luo

Lai

2015

Biochemical Pharmacology

View full text Add to dashboard Cite

Section: Page 26 Of 64mentioning

confidence: 98%

Biological effects of interleukin-6: Clinical applications in autoimmune diseases and cancers

Luo

Lai

2015

Biochemical Pharmacology

View full text Add to dashboard Cite

“…More familiar to rheumatologists and internists is the use of TCZ in adult-onset Still's disease (AOSD), particularly in patients who are refractory to conventional therapies and present a predominant polyarticular pattern of the disease [14][15][16]. AOSD is a rare multisystem inflammatory disease of unknown origin that is included within the clinical spectrum of autoinflammatory disorders [16,17].…”

Section: The Role Of Tocilizumab In Systemic Autoimmune and Inflammatmentioning

confidence: 99%

Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces

Mayo

Castañeda

Cifrián

et al. 2020

Expert Opinion on Biological Therapy

Self Cite

View full text Add to dashboard Cite

“…No published prospective clinical trials evaluating TCZ in AOSD are available, but promising efficacy results have been observed in several case reports and retrospective analyses [84][85][86][87]. Improvements in clinical (fever, rash, and myalgia) and laboratory (ESR and CRP) manifestations were observed after treatment with TCZ in a review of 24 cases of AOSD in Korean patients [88].…”

Section: Other Diseasesmentioning

confidence: 99%

A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases

et al. 2018

View full text Add to dashboard Cite

Tocilizumab (TCZ) is the first humanized antiinterleukin-6 (IL-6) receptor monoclonal antibody approved for the treatment of patients with rheumatoid arthritis (RA), Castleman's disease, polyarticular and systemic juvenile idiopathic arthritis, and, most recently, giant cell arteritis as well as for the treatment of chimeric antigen receptor T cell therapy-induced cytokine release syndrome. The global clinical development program for TCZ provides a wealth of clinical data on intravenous TCZ, and more recent studies in patients with RA have provided evidence characterizing the role of intravenous TCZ as monotherapy in early disease and led to the introduction of a subcutaneous formulation of TCZ. In addition, recently published open-label extension and observational studies continue to support the longterm efficacy and safety of TCZ in both clinical trial and real-world settings. Given the involvement of IL-6-mediated signaling in inflammatory disorders, TCZ is also being investigated in other immunological diseases. In particular, a phase 2 trial on the safety and efficacy of subcutaneous TCZ in adults with systemic sclerosis shows clinically relevant improvements in skin sclerosis and lung function in these patients. Another anti-IL-6 receptor agent, sarilumab, targeting the IL6 receptor alpha subunit, was recently approved for the treatment of patients with RA, although longterm data for this biologic are not yet published. In this article we review the placement of TCZ in current treatment guidelines; recent clinical trial data, including quality of life in patients with RA; recent updates to the TCZ safety profile; recent investigations of TCZ in other immunological diseases; and the clinical development of other novel IL-6-targeted agents. Keywords: Interleukin-6; Rheumatoid arthritis; Tocilizumab TOCILIZUMAB: THE FIRST INTERLEUKIN-6 RECEPTOR-NEUTRALIZING BIOLOGICInterleukin-6 (IL-6) is a multifunctional cytokine that plays an important role in both acute and chronic inflammatory responses. Consequently, the dysregulated or persistent production of IL-6 can lead to the development of inflammatory disorders [1]. Elevated levels of IL-6 in serum, synovial fluid, and various tissues have been correlated with disease activity in patients with rheumatoid arthritis (RA) [2], juvenile idiopathic arthritis (JIA) [3,4], Castleman's disease [5,6], systemic sclerosis (SSc) [7], giant cell arteritis (GCA) [8,9], adult-onset Still's disease (AOSD) [10], familial Mediterranean fever (FMF) [11,12], Schnitzler's syndrome [13,14], polychondritis [15], and amyloidosis [1]. These associations suggest a pathogenetic role for IL-6 in multiple inflammatory conditions and form the basis of the rationale for the development of anti-IL-6 therapies.Tocilizumab (TCZ) is the first humanized monoclonal antibody targeting the IL-6 receptor subunit alpha (IL-6Ra) [16], and its mechanism of action has been described in detail in previous reviews [17,18]. Briefly, TCZ targets both membrane-bound and soluble IL-6Ra, which prevents t...

show abstract

Efficacy of Tocilizumab in Conventional Treatment–Refractory Adult‐Onset Still's Disease: Multicenter Retrospective Open‐Label Study of Thirty‐Four Patients

Cited by 119 publications

References 13 publications

Biological effects of interleukin-6: Clinical applications in autoimmune diseases and cancers

Biological effects of interleukin-6: Clinical applications in autoimmune diseases and cancers

Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces

A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases

Contact Info

Product

Resources

About